VVOS · Vivos Therapeutics Inc
AI read · Good for VVOS
The AI's read
Vivos reported Q2 revenue up 35% to $5.2M and called out an acquisition, treatment-center expansion, and new partnerships. Those items point to service and remote-monitoring revenue growth, which is higher margin and more recurring. The market barely moved, up ~1.1%, and RSI sits near 69, so the headline beat looks only partially priced in. Microcap execution and NASDAQ funding risks still matter given the tiny market cap and low stock price. Bottom line: we lean bullish because growth plus a clear path to positive cash flow late 2026 offers asymmetric upside. Conviction 84% — fresh news and a plan, but execution and dilution are real downsides.